Citations

Showing 10 of 108094 citations.

Omalizumab as a treatment option for antihistamine-refractory aquagenic urticaria
Kaur, Sehajpreet, Bhasin, Arveen Kaur, Jabbal, Iktej Singh , Bhasin, Arveen

Mayo Clinic

BMJ Case Reports | July 18, 2022 | Volume: 15 | Issue: 7 | Pages: e251057

10.1136/bcr-2022-251057 | PMID 35850790 Get It

A teenage girl presented with symptoms of itching and hives on contact with water for 3 years. On specific provocative testing and ruling out underlying systemic conditions, she was diagnosed with aquagenic urticaria. Following failed attempts to control her symptoms with second-generation antihistamines, she was started on monthly subcutaneous injections of the monoclonal antibody, omalizumab. The patient demonstrated significant improvement, with symptoms being well-controlled for 2 years now. She enjoys a good quality of life and can take a shower without developing itching or hives.
Heart transplantation in Val142Ile mutation in the modern era: A single center experience
Lyle, Melissa , Brown, Matthew T. , Morris, Alanna A. , Gupta, Divya , Vega, J. David , Cole, Robert , Bhatt, Kunal , Lyle, Melissa A

Mayo Clinic

Clinical Transplantation | July 18, 2022 | Volume: 36 | Issue: 11 | Pages: No page available

10.1111/ctr.14780 | PMID 35848634 Get It

AbstractLittle is known about the post heart transplantation management of extra cardiac manifestations in patients with hereditary transthyretin amyloid cardiomyopathy (hATTR‐CM) in the new era of disease modifying treatment for ATTR amyloidosis. This is a retrospective study of all patients with hATTR‐CM associated with the Val142Ile variant who underwent heart transplantation (HT) from January 2014 to February 2022. All 10 patients with the Val142Ile mutation were successfully transplanted, with a 1 year survival post heart transplantation (HT) of 90%, comparable to an age, sex, and race matched cohort of patients transplanted for non‐amyloid indications. However, 4 (40%) of these patients developed progressive extracardiac manifestations requiring initiation of TTR silencer therapy with the small interfering RNA (siRNA) drug patisiran, which was well tolerated with no significant side effects in this population. We recommend formal neurologic evaluation and assessment of extracardiac manifestations annually as part of routine post‐transplant care, and disease modifying therapy, aimed at TTR stabilization or silencing, should be initiated in the context of previously untreated extracardiac manifestations or evidence of subclinical neuropathy to prevent progression.
Acetylated HOXB13 Regulated Super Enhancer Genes Define Therapeutic Vulnerabilities of Castration-Resistant Prostate Cancer
Nguyen, Duy T. , Yang, Wei , Renganathan, Arun , Weimholt, Cody , Angappulige, Duminduni H. , Nguyen, Thanh , Sprung, Robert W. , Andriole, Gerald L. , Kim, Eric H. , Mahajan, Nupam P. , Mahajan, Kiran

Mayo Clinic

Clinical Cancer Research | July 18, 2022 | Volume: 28 | Issue: 18 | Pages: 4131-4145

10.1158/1078-0432.ccr-21-3603 | PMID 35849143 Get It

Abstract Purpose: Androgen receptor (AR) antagonism is exacerbated by HOXB13 in castration-resistant prostate cancers (CRPC). However, it is unclear when and how HOXB13 primes CRPCs for AR antagonism. By mass-spectrometry analysis of CRPC extract, we uncovered a novel lysine 13 (K13) acetylation in HOXB13 mediated by CBP/p300. To determine whether acetylated K13-HOXB13 is a clinical biomarker of CRPC development, we characterized its role in prostate cancer biology. Experimental Design: We identified tumor-specific acK13-HOXB13 signal enriched super enhancer (SE)-regulated targets. We analyzed the effect of loss of HOXB13K13-acetylation on chromatin binding, SE proximal target gene expression, self-renewal, enzalutamide sensitivity, and CRPC tumor growth by employing isogenic parental and HOXB13K13A mutants. Finally, using primary human prostate organoids, we evaluated whether inhibiting an acK13-HOXB13 target, ACK1, with a selective inhibitor (R)-9b is superior to AR antagonists in inhibiting CRPC growth. Results: acK13-HOXB13 promotes increased expression of lineage (AR, HOXB13), prostate cancer diagnostic (FOLH1), CRPC-promoting (ACK1), and angiogenesis (VEGFA, Angiopoietins) genes early in prostate cancer development by establishing tumor-specific SEs. acK13-HOXB13 recruitment to key SE-regulated targets is insensitive to enzalutamide. ACK1 expression is significantly reduced in the loss of function HOXB13K13A mutant CRPCs. Consequently, HOXB13K13A mutants display reduced self-renewal, increased sensitivity to enzalutamide, and impaired xenograft tumor growth. Primary human prostate tumor organoids expressing HOXB13 are significantly resistant to AR antagonists but sensitive to (R)-9b. Conclusions: In summary, acetylated HOXB13 is a biomarker of clinically significant prostate cancer. Importantly, PSMA-targeting agents and (R)-9b could be new therapeutic modalities to target HOXB13–ACK1 axis regulated prostate cancers.
Sign of the times: Community engagement to refine a cardiovascular mHealth intervention through a virtual focus group series during the COVID-19 Pandemic
Brewer, LaPrincess C. , Cyriac, Jissy , Kumbamu, Ashok , Jenkins, Sarah M. , Hayes, Sharonne N. , Hayes, Sharonne N , Patten, Christi A. , Brewer, LaPrincess C , Burke, Lora E. , Jones, Clarence , Cooper, Lisa A.

Mayo Clinic

DIGITAL HEALTH | July 18, 2022 | Volume: 8 | Issue: No issue available | Pages: 205520762211105

10.1177/20552076221110537 | PMID 35874864 Get It

Background African-Americans are underrepresented in mobile health intervention research studies which can perpetuate health inequities and the digital divide. A community-based, user-centered approach to designing mobile health interventions may increase their sociocultural relevance and effectiveness, especially with increased smartphone use during the coronavirus disease 2019 pandemic. We aimed to refine an existing mobile health intervention via a virtual focus group series. Methods African-American community members (n = 15) from churches in Minneapolis-St. Paul and Rochester, Minnesota were enrolled in a virtual (via videoconferencing), three-session focus group series over five months to refine a cardiovascular health-focused mobile health application (FAITH! [Fostering African-American Improvement in Total Health!] App). Participants accessed the app via their smartphones and received a Fitbit synced to the app. Participants engaged with multimedia cardiovascular health-focused education modules, a sharing board for social networking, and diet/physical activity self-monitoring. Participant feedback on app features prompted iterative revisions to the FAITH! App. Primary outcomes were app usability (assessed via Health Information Technology Usability Evaluation Scale range: 0–5) and user satisfaction. Results Participants (mean age [SD]: 56.9 [12.3] years, 86.7% female) attended a mean 2.8 focus groups (80% attended all sessions). The revised FAITH! App exceeded the goal Health Information Technology Usability Evaluation Scale score threshold of ≥4 (mean: 4.39, range: 3.20–4.95). Participants positively rated updated app content, visual appeal, and use of social incentives to maintain engagement. Increasing user control and refinement of the moderated sharing board were identified as areas for future improvement. Conclusions Community-partnered, virtual focus groups can optimize usability and increase participant satisfaction of mobile health lifestyle interventions that aim to promote cardiovascular health in African-Americans.
Induction therapy in lung transplantation: A contemporary analysis of trends and outcomes
Shagabayeva, Larisa , Osho, Asishana A. , Moonsamy, Philicia , Mohan, Navyatha, Li, Selena S. , Wolfe, Stanley B. , Langer, Nathaniel B. , Funamoto, Masaki , Villavicencio, Mauricio A. , Li, Selena Shi-Yao , Wolfe, Stanley , Osho, Asishana , Funamoto, Masaki

Mayo Clinic

Clinical Transplantation | July 18, 2022 | Volume: 36 | Issue: 11 | Pages: No page available

10.1111/ctr.14782 | PMID 35848518 Get It

AbstractObjectivesWe provide a contemporary consideration of long‐term outcomes and trends of induction therapy use following lung transplantation in the United States. Methods: We reviewed the United Network for Organ Sharing registry from 2006 to 2018 for first‐time, adult, lung‐only transplant recipients. Long‐term survival was compared between induction classes (Interleukin‐2 inhibitors, monoclonal or polyclonal cell‐depleting agents, and no induction therapy). A 1:1 propensity score match was performed, pairing patients who received basiliximab with similar risk recipients who did not receive induction therapy. Outcomes in matched populations were compared using Cox, Kaplan‐Meier and Logistic regression modeling.Measurements and main results22 025 recipients were identified; 8003 (36.34%) were treated with no induction therapy, 11 045 (50.15%) with basiliximab, 1556 (7.06%) with alemtuzumab and 1421 (6.45%) with anti‐thymocyte globulin. Compared with those who received no induction, patients receiving basiliximab, alemtuzumab or anti‐thymocyte globulin were found on multivariable Cox‐regression analyses to have lower long‐term mortality (all p < .05). Following propensity score matching of basiliximab and no induction populations, analyses demonstrated a statistically significant association between basiliximab use and long‐ term survival (p < .001). Basiliximab was also associated with a lower risk of acute rejection (p < .001) and renal failure (p = .002).ConclusionInduction therapy for lung transplant recipients—specifically basiliximab—is associated with improved long‐term survival and a lower risk of renal failure or acute rejection.
A 44‐year‐old man with esophageal ulcer
Fogwe, Delvise T. , Ho, Matthew T., Shah, Aditya , Shah, Aditya S

Mayo Clinic

Clinical Case Reports | July 18, 2022 | Volume: 10 | Issue: 7 | Pages: No page available

10.1002/ccr3.6044 | PMID 35865767 Get It

GLS1 is a Protective Factor in Patients with Ovarian Clear Cell Carcinoma and its Expression Does Not Correlate with ARID1A-mutated Tumors
Clemente, Valentino , Hoshino, Asumi , Shetty, Mihir , Erickson, Britt , Baker, R. W. R. , Khalifa, Mahmoud A. , Weroha, S. John , Lou, Emil , Bazzaro, Martina , Erickson, Britt K , Lou, Emil , Nelson, Andy , Baker, Ruth, Rubin, Nathan

Mayo Clinic

Cancer Research Communications | July 18, 2022 | Volume: 2 | Issue: 8 | Pages: 784-794

10.1158/2767-9764.crc-22-0122 | PMID 36082022 Get It

Targeting glutamine metabolism has emerged as a novel therapeutic strategy for several human cancers, including ovarian cancer. The primary target of this approach is the kidney isoform of glutaminase, glutaminase 1 (GLS1), a key enzyme in glutamine metabolism that is overexpressed in several human cancers. A first-in-class inhibitor of GLS1, called CB839 (Telaglenastat), has been investigated in several clinical trials, with promising results. The first clinical trial of CB839 in platinum-resistant patients with ovarian cancer is forthcoming. ARID1A-mutated ovarian clear cell carcinoma (OCCC) is a relatively indolent and chemoresistant ovarian cancer histotype. In OCCC-derived cells ARID1A simultaneously drives GLS1 expression and metabolism reprograming. In ARID1A-mutated OCCC-derived mouse models, loss of ARID1A corresponds to GLS1 upregulation and increases sensitivity to GLS1 inhibition. Thus, targeting of GLS1 with CB839 has been suggested as a targeted approach for patients with OCCC with tumors harboring ARID1A mutations. Here, we investigated whether GLS1 is differentially expressed between patients with OCCC whose tumors are ARID1A positive and patients whose tumors are ARID1A negative. In clinical specimens of OCCC, we found that GLS1 overexpression was not correlated with ARID1A loss. In addition, GLS1 overexpression was associated with better clinical outcomes. Our findings have implications for human trials using experimental therapeutics targeting GLS1. Significance: GLS1 differential expression in patients with OCCC with or without ARID1A mutations is significant because a clinical trial with a GLS1 inhibitor is forthcoming. Tumors without ARID1A have low levels of GLS1 and GLS1 expression is associated to better outcome. Thus, blockade of GLS1 could be counterproductive for patients with OCCC.
Estimating the accuracy of dual energy chest radiography for coronary calcium detection with lateral or anteroposterior orientations
Hsieh, Scott S. , Budoff, Matthew J.

Mayo Clinic

Medical Physics | July 18, 2022 | Volume: 49 | Issue: 9 | Pages: 5763-5772

10.1002/mp.15855 | PMID 35848231 Get It

AbstractPurposeCoronary artery calcium (CAC) scoring with CT has been studied as a risk stratification tool for cardiovascular disease. However, concerns remain from the radiation dose, economic expense, and incidental findings associated with this exam. Dual energy chest X‐ray (DE CXR) has been proposed as an alternative, but validation of this technique remains limited. The purpose of this work was twofold: first, to estimate the sensitivity and specificity of DE CXR using simulation of patient datasets in a CAC screening cohort; second, to assess if sensitivity and specificity could be improved using a lateral instead of an anteroposterior (AP) orientation.MethodsWe started from a cohort of 73 CAC scoring CT exams after exclusions for metal wires, data truncation, or with age outside 40–75 years. The fraction of CT CAC scores in the validation set of 0, 1–99, 100–299, and 300+ were 36, 25, 14, and 26%, respectively. CT datasets were decomposed on a voxel‐by‐voxel basis into mixtures of water and calcium according to CT number. DE CXR images were simulated using polyenergetic forward projection with scatter estimated from Monte Carlo. We assumed a technique of 60 and 120 kVp for the dual energy acquisition. The tube current was scaled such that the estimated radiation dose from DE CXR was 10 times less than CAC scoring CT. Patient motion was not simulated. Two readers read the validation set in a blinded, randomized fashion, and estimated the amount of CAC in each DE CXR image using a semiquantitative 4‐point scale. Although patients present on a spectrum of CAC severity, in the primary analysis, sensitivity and specificity were calculated by dichotomizing patients into two categories of CT CAC (Agatston) scores of either 0–99 or 100+.ResultsFrom the lateral orientation, average sensitivity between two readers was 69% (range, 69–69%), specificity was 85% (range, 84–86%), and area under the curve (AUC) was 0.81 (range, 0.80–0.81). From the AP orientation, average sensitivity was 35% (range, 31–38%), average specificity was 70% (range, 66–73%), and AUC was 0.54 (range, 0.53–0.55). Reader DE CXR scores agreed within 1 point of the 4‐point scale on 97% of ratings from the lateral orientation and 80% from the AP orientation. From the lateral orientation, AUC increased when considering higher CT CAC score thresholds as disease positive; for thresholds of 1+, 300+, and 1000+, average AUC was 0.72, 0.81, and 0.92, respectively. From the AP orientation, AUC was 0.57, 0.55, and 0.61, respectively.ConclusionsDE CXR for CAC scoring may have higher diagnostic accuracy when acquired from the lateral orientation. The sensitivity and specificity of lateral DE CXR, when combined with its modest cost and radiation dose, suggest a possible role for this technique in screening coronary calcium in lower risk individuals. These estimates of diagnostic accuracy are derived from simulation of patient datasets and have not been corroborated with experimental or clinical images.
Outcomes of bebtelovimab and sotrovimab treatment of solid organ transplant recipients with mild‐to‐moderate coronavirus disease 2019 during the Omicron epoch
Yetmar, Zachary A. , Beam, Elena , Seville, Maria Teresa , Brumble, Lisa , Razonable, Raymund R. , Razonable, Raymund R , Yetmar, Zachary A , Beam, Elena , O’Horo, John C. , Ganesh, Ravindra

Mayo Clinic

Transplant Infectious Disease | July 18, 2022 | Volume: 24 | Issue: 4 | Pages: No page available

10.1111/tid.13901 | PMID 35848574 Get It

Abstract Background Solid organ transplant recipients (SOTRs) are at high‐risk for severe infection from severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). Anti‐spike monoclonal antibodies are currently utilized under emergency use authorization to prevent hospitalization in high‐risk individuals with coronavirus disease 2019 (COVID‐19), including SOTRs. However, clinical data for bebtelovimab, the sole currently available anti‐spike monoclonal antibody for COVID‐19, is limited. Methods We conducted a retrospective cohort study of adult SOTRs diagnosed with mild‐to‐moderate COVID‐19 from January 2022 through May 2022 who received either bebtelovimab or sotrovimab. The primary outcome was COVID‐19‐related hospitalization within 30 days of COVID‐19 diagnosis. Data were analyzed with Fisher's exact test. Results Among 361 SOTRs, 92 (25.5%) received bebtelovimab and 269 (74.5%) received sotrovimab. The most common organ transplant was a kidney (42.4%). SOTRs who received bebtelovimab had a higher proportion who had received a booster SARS‐CoV‐2 vaccine dose and had received their last vaccination dose more recently. Eleven (3.0%) SOTRs were hospitalized, and rates of hospitalization were similar between monoclonal antibody groups (3.3% versus 3.0%; p > .99). Three patients required admission to an intensive care unit, all of who received sotrovimab. Four (1.1%) patients died within 30 days of COVID‐19 diagnosis, two from each group. Conclusions SOTRs with mild‐to‐moderate COVID‐19 who received bebtelovimab had similar rates of COVID‐19‐related hospitalization as those who received sotrovimab. While differences in vaccination rates and viral subvariants could act as confounders, bebtelovimab appears to be of similar effectiveness as sotrovimab. image
The COVID ‐19 pandemic and its consequences for chronic pain: a narrative review
Shanthanna, Harsha , Nelson, Ariana M. , Kissoon, Narayan , Narouze, Samer

Mayo Clinic

Anaesthesia | July 18, 2022 | Volume: 77 | Issue: 9 | Pages: 1039-1050

10.1111/anae.15801 | PMID 35848380 Get It

Summary The COVID‐19 pandemic transformed everyday life, but the implications were most impactful for vulnerable populations, including patients with chronic pain. Moreover, persistent pain is increasingly recognised as a key manifestation of long COVID. This narrative review explores the consequences of the COVID‐19 pandemic for chronic pain. Publications were identified related to the COVID‐19 pandemic influence on the burden of chronic pain, development of new‐onset pain because of long COVID with proposed mechanisms and COVID‐19 vaccines and pain interventions. Broadly, mechanisms underlying pain due to SARS‐CoV‐2 infection could be caused by ‘systemic inflammatory‐immune mechanisms’, ‘direct neuropathic mechanisms’ or ‘secondary mechanisms due to the viral infection or treatment’. Existing chronic pain populations were variably impacted and social determinants of health appeared to influence the degree of effect. SARS‐CoV‐2 infection increased the absolute numbers of patients with pain and headache. In the acute phase, headache as a presenting symptom predicted a milder course. New‐onset chronic pain was reportedly common and likely involves multiple mechanisms; however, its prevalence decreases over time and symptoms appear to fluctuate. Patients requiring intensive support were particularly susceptible to long COVID symptoms. Some evidence suggests steroid exposure (often used for pain interventions) may affect vaccine efficacy, but there is no evidence of clinical repercussions to date. Although existing chronic pain management could help with symptomatic relief, there is a need to advance research focusing on mechanism‐based treatments within the domain of multidisciplinary care.